Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AZTREONAM Cause Concomitant disease aggravated? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Concomitant disease aggravated have been filed in association with AZTREONAM (AZACTAM). This represents 0.4% of all adverse event reports for AZTREONAM.

7
Reports of Concomitant disease aggravated with AZTREONAM
0.4%
of all AZTREONAM reports
3
Deaths
7
Hospitalizations

How Dangerous Is Concomitant disease aggravated From AZTREONAM?

Of the 7 reports, 3 (42.9%) resulted in death, 7 (100.0%) required hospitalization, and 3 (42.9%) were considered life-threatening.

Is Concomitant disease aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AZTREONAM. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does AZTREONAM Cause?

Off label use (195) Dyspnoea (184) Eosinophilia (161) Cough (123) Drug hypersensitivity (116) Pyrexia (107) Wheezing (103) Infective pulmonary exacerbation of cystic fibrosis (99) Asthma (94) Rash (82)

What Other Drugs Cause Concomitant disease aggravated?

SACUBITRIL\VALSARTAN (533) SECUKINUMAB (461) FINGOLIMOD (425) MACITENTAN (286) OMALIZUMAB (186) SELEXIPAG (166) METHOTREXATE (150) RUXOLITINIB (142) OCTREOTIDE (125) BOSENTAN (123)

Which AZTREONAM Alternatives Have Lower Concomitant disease aggravated Risk?

AZTREONAM vs AZTREONAM LYSINE AZTREONAM vs BACILLUS CALMETTE-GUERIN ANTIGEN, UNSPECIFIED SUBSTRAIN AZTREONAM vs BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN AZTREONAM vs BACITRACIN AZTREONAM vs BACITRACIN\NEOMYCIN\POLYMYXIN B

Related Pages

AZTREONAM Full Profile All Concomitant disease aggravated Reports All Drugs Causing Concomitant disease aggravated AZTREONAM Demographics